Take the Win, Stay Selective
The market still deserves a constructive stance, but constructive does not mean patient with everything. Tonight's review came down to two decisions: let a winner go while it is still a winner, and treat a new idea as a candidate rather than an order.
## The planned close: BMY
The BMY bull call spread has done its job. The squeeze fired, the move came, and now the follow-through is fading. I would rather protect the gain than sit through another warning bar hoping for one more leg. There is no exit price yet and no order working; this is an exit to assess in the session, not a completed sale.
The lesson I keep relearning: the reason to stay in a trade is not the same as the hope of squeezing every last dollar out of it.
## The new candidate: Embraer
The setup is a bullish call on Embraer expiring in October. Several support levels line up under price, including a prior high and retracement levels, which gives a defined area where the idea should either work or fail. A nearer-dated call spread was considered and rejected because the debit was more than half the width; the single October call was the cleaner structure.
The reference price I have is Friday's closing mid, not a live quote or a firm limit. Before this becomes an order I need to confirm the exact underlying and contract. A watchlist idea is not an executable trade until that is done.
## Everything else is patience and confirmation
- XBI stays a support-and-time-stop setup. It needs follow-through, and I am not going to force a deadline on it.
- Barrick and Charles Schwab remain holds. Schwab's developing squeeze argues for waiting, not adding.
- Shopify needs closer attention after its attempted rally failed to hold.
- APA stays on as energy exposure.
- CRH and VXX were earlier exits, not new closes tonight.
- SIL is the reminder: a bounce off support is not enough when resistance sits directly overhead. I want momentum or a squeeze before assuming that ceiling breaks.
My takeaway is simple: protect gains when momentum weakens, keep a clear line between a watchlist idea and an order, and verify the contract before acting.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
- zuzu99·09-09XBI is the part that really needs patience. Valuation spread in biotech is huge right now, so index support alone means less than clean pipelines and real cash flow.LikeReport
- DIMCO·09-09Protecting BMY here makes sense, but the October ERJ call feels a bit aggressive. I’d wait for a clean reclaim of the prior high before treating it like a real setupLikeReport